EXOMIND® entered the U.S. market in 2025 through major depressive disorder (MDD) indications for adult patients. The new clearances expand its reach to additional brain targets and conditions, including obsessive-compulsive disorder (OCD), MDD comorbid anxiety, and extend care to adolescent patients. Additionally, EXOMIND® now offers an intermittent theta burst protocol with treatment sessions as short as three minutes, giving providers more ways to care for their patients. Further expanding the platform’s capabilities, BTL introduces the new EXOMIND® Dual Applicator, broadening treatment possibilities and giving providers greater flexibility to personalize patient care.
“OCD is among the most common mental health disorders worldwide, and it can turn everyday routines into a constant struggle,” said Dennis Weimer, MD, a physician triple board-certified in Psychiatry, Consultation-Liaison Psychiatry, and Addiction Medicine. “In my practice, EXOMIND® has been an effective, comfortable treatment for patients with depression. Now I can offer another treatment option to adults whose lives are disrupted by OCD, while reaching more patients with depression and anxiety symptoms. With theta burst, a MDD treatment session can take as little as three minutes—making care easier to fit into their lives.”